Search

Search results

399 results found

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp, K A, A Blauvelt, A B Kimball, C Han, B Randazzo, Y Wasfi, Y-K Shen, S Li, and C E M Griffiths. 2018. “Patient-Reported Symptoms and Signs of Moderate-to-Severe Psoriasis Treated With Guselkumab or Adalimumab: Results from the Randomized VOYAGE 1 Trial.”. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (9): 1515-22.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths, Christopher E M, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, and Andrew Blauvelt. 2018. “Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.”. Journal of Drugs in Dermatology : JDD 17 (8): 826-32.

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.

Zachariae, Claus, Kenneth Gordon, Alexandra B Kimball, Mark Lebwohl, Andrew Blauvelt, Craig Leonardi, Daniel Braun, Missy McKean-Matthews, Russel Burge, and Gregory Cameron. 2018. “Efficacy and Safety of Ixekizumab over 4 years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis.”. Journal of the American Academy of Dermatology 79 (2): 294-301.e6.

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.

Zouboulis, C C, T Tzellos, A Kyrgidis, G B E Jemec, F G Bechara, E J Giamarellos-Bourboulis, J R Ingram, et al. 2017. “Development and Validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a Novel Dynamic Scoring System to Assess HS Severity.”. The British Journal of Dermatology 177 (5): 1401-9.

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.

Kimball, A B, G B E Jemec, M Yang, A Kageleiry, J E Signorovitch, M M Okun, Y Gu, K Wang, P Mulani, and M Sundaram. 2014. “Assessing the Validity, Responsiveness and Meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) As the Clinical Endpoint for Hidradenitis Suppurativa Treatment.”. The British Journal of Dermatology 171 (6): 1434-42.